KLDO

0.00010.00%
AG

Anthony G. Quinn

Independent Director

Dr. Anthony G. Quinn, M.B. Ch.B., Ph.D., MD, FRCP, has been Member of Scientific Advisory Board at Anokion SA. Dr. Quinn served as President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. since July 19, 2018 until August 24, 2022 and was its Principal Financial Officer since March 16, 2021 until July 06, 2021. Dr. Quinn has served as a Director of Kaleido BioSciences, Inc. since February 2016. Dr. Quinn served as Interim Chief Executive Officer of Aeglea BioTherapeutics since July 2017 until July 19, 2018. Dr. Quinn served as Independent Director of Generation Bio Co. since December 2017 until February 06, 2026. Dr. Quinn served as Interim Chief Medical Officer of Aeglea Biotherapeutics, Inc. from April 21, 2017 to July 10, 2017. Dr. Quinn served as the Chief Medical Officer of Synageva BioPharma Corp. since August 2009 until June 2015 and served as its Executive Vice President from January 2014 to June 2015. Dr. Quinn served as the Senior Vice President and Head of Research & Development at Synageva BioPharma Corp. since August 2009 until January 2014. Dr. Quinn joined Synageva from Roche Palo Alto, LLC where, from September 2004 until joining Synageva, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation Disease Biology. Since October 2015 until July 2017, Dr. Quinn worked as a private consultant for IDBioPharm Consulting LLC from August 2009 to June 2015. While at Roche, Dr. Quinn managed programs in rheumatology and respiratory indications in exploratory development and biomarker and translational medicine activities in the late clinical and registration phase for MabThera™/Rituxan™, Actemra™ and Ocrelizumab. He joined Roche Palo Alto in 2005 to build the translational medicine and exploratory development capabilities at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche, he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK and he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He serves on the boards of directors at Kaleido Biosciences, Incorporated. He served as a Director of Aeglea Biotherapeutics, Inc. since April 2015 until August 24, 2022. Dr. Quinn worked for Alexion Pharmaceuticals from June 2015 to September 2015. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on Hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Sciences (B.MSc ) in General Pathology with First class honors and his M.B. Ch.B. (M.D.) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the from the University of Newcastle in Tyne, UK and was also awarded his Ph.D. degree in Cancer Research there. He completed a postdoctoral fellowship at University of California, San Francisco and is a fellow of the Royal College of Physicians London.

Positions